Sanara MedTech Inc 8-K, filed Oct 16, 2020
Sanara MedTech Inc. (SMTI)
8-K
2020-10-16
For: 2020-10-12
View Original
Added on
April 11, 2026
About this 8-K
Sanara MedTech Inc filed this 8-K on October 16, 2020, reporting on events of October 12, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): October 12,
2020
SANARA MEDTECH INC.
(Exact
name of registrant as specified in its charter)
|
Texas
|
000-11808
|
59-2219994
|
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
No.)
|
|
1200 Summit Avenue, Suite
414
Fort
Worth, Texas
|
76102
|
|
(Address of principal executive
offices)
|
(zip code)
|
Registrant’s
telephone number, including area code: (817)-529-2300
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant Section 12(b) of the Act: None
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
--
|
--
|
--
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective October
12, 2020, the Board of Directors (the “Board”) of
Sanara MedTech Inc. (the “Company”) appointed Robert A.
DeSutter to the Company’s Board. Mr. DeSutter is a managing
director in Piper Sandler healthcare investment banking. He has
twenty-seven years of experience in healthcare investment banking
at Piper Sandler and served as global group head from 2003 to 2018.
Over that period, the group became one of the leading and most
respected healthcare investment banking practices. Mr. DeSutter is
a graduate of the University of Minnesota and the University of
Virginia's Darden Graduate School of Business. The Company believes
the addition of Mr. DeSutter to its Board represents an important
step in the Company’s growth plans.
The
Company anticipates that Mr. DeSutter will be appointed to the
audit committee. If the Board elects to form a nominating and
corporate governance committee, the Company anticipates that Mr.
DeSutter would be appointed to that committee.
Item
7.01 Regulation FD Disclosure.
On
October 15, 2020, the Company issued a press release announcing the
appointment of Mr. DeSutter to the Board. A copy of the press
release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
The
information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that Section. Further, the information in
Item 7.01 of this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as
amended. Item 7.01 of this Current Report on Form 8-K will not be
deemed an admission as to the materiality of any information in
this Current Report on Form 8-K that is required to be disclosed
solely by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits:
|
Exhibit
No.
|
|
Description
|
|
|
Press
Release issued October 15, 2020 (furnished pursuant to Item
7.01).
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Sanara
MedTech Inc.
|
|
|
|
|
|
|
|
|
Date:
October 16, 2020
|
By:
|
/s/
Michael D. McNeil
|
|
|
|
|
Name:
Michael D. McNeil
|
|
|
|
|
Title:
Chief Financial Officer
|
|
Exhibit 99.1
Sanara
MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board
of Directors
FORT WORTH, TX / ACCESSWIRE / October 15, 2020 / Sanara MedTech
Inc. Based in Fort Worth, Texas, Sanara MedTech Inc.
("Sanara" or the "Company") (OTCQB:SMTI), a provider of wound and
skin care products and virtual consult services dedicated to
improving patient outcomes, announced today that Bob DeSutter has
been appointed to the Company's Board of Directors (the "Board"),
effective October 12, 2020.
Ron
Nixon, Sanara's Executive Chairman stated, "Bob is a great addition
to our Board. He has a wealth of knowledge and experience in the
medtech segment of the healthcare industry, and we believe that he
will provide great judgement, insights, and disruptive thinking as
we continue to execute on our long-term comprehensive wound and
skin care strategy."
Bob
DeSutter is a managing director in Piper Sandler healthcare
investment banking. He has 27 years of healthcare investment
banking experience at Piper Sandler and served as global group head
from 2003 to 2018. Over that period, the group became one of the
leading and most respected healthcare investment banking
practices.
"I have
been following Sanara's product cadence and growth for many years
and am honored to join the Board and assist the Company in
executing its strategy in the advanced wound and skin care
markets," said DeSutter.
About Sanara MedTech Inc.
With a
focus on improving patient outcomes through evidence-based healing
solutions, Sanara MedTech Inc. markets and distributes wound and
skin care products and services to physicians, hospitals, clinics,
and all post-acute care settings. We are constantly seeking
long-term strategic partnerships with a focus on products that
produce efficacious outcomes at a lower overall cost. Our products
are primarily sold in the North American advanced wound care and
surgical tissue repair markets. Sanara MedTech markets and
distributes CellerateRX® Surgical
Activated Collagen® to the surgical
markets as well as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser,
HYCOL™ Hydrolyzed Collagen, and PULSAR II™ Advanced
Wound Irrigation™ (AWI). In addition, Sanara is actively
seeking to expand within its six focus areas of wound and skin care
for the acute, post-acute, and surgical markets. The focus areas
are debridement, biofilm removal, hydrolyzed collagen, advanced
biologics, negative pressure wound therapy adjunct products, and
the oxygen delivery system segment of the healthcare industry. For
more information, visit SanaraMedTech.com.
Information about Forward-Looking Statements
The
statements in this press release that do not constitute historical
facts are "forward-looking statements," within the meaning of and
subject to the safe harbor created by the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by terms such as "may," "will," "would," "should," "expect,"
"plan," "anticipate," "could," "intend," "target," "project,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negatives of these terms, variations of these
terms or other similar expressions. These forward-looking
statements include statements regarding the development of new
products and expansion of the Company's business in telehealth and
wound care. These items involve risks, contingencies and
uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition,
pricing, the ability to consummate and integrate acquisitions, and
other risks, contingencies and uncertainties detailed in the
Company's SEC filings, which could cause the Company's actual
operating results, performance or business plans or prospects to
differ materially from those expressed in, or implied by these
statements. All forward-looking statements speak only as of the
date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon
Nichols
Director
of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.